MYB-NFIB fusion + BCOR F1106Tfs*5 + BCOR L1524Hfs*8
MYB-NFIB fusion + BCOR F1106Tfs*5 + BCOR L1524Hfs*8
|
Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
|
anlotinib + eribulin mesylate
Sensitive: C4 – Case Studies
Anticancer Drugs - 1 week
|
MYB underexpression
MYB underexpression
|
Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
|
tretinoin
Sensitive: C3 – Early Trials
|
NOTCH1 mutation
NOTCH1 mutation
|
Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
|
tretinoin
Sensitive: C3 – Early Trials
|
NOTCH1 positive + FGFR2 mutation
NOTCH1 positive + FGFR2 mutation
|
Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
|
lenvatinib + erdafitinib + γ-secretase inhibitor
Sensitive: C4 – Case Studies
|
MYB-NFIB fusion
MYB-NFIB fusion
|
Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
|
M6620
Sensitive: D – Preclinical
|
PIK3CA mutation
PIK3CA mutation
|
Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
|
tretinoin
Sensitive: D – Preclinical
|
PIK3CA amplification
PIK3CA amplification
|
Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
|
tretinoin
Sensitive: D – Preclinical
|
MYB-NFIB fusion
MYB-NFIB fusion
|
Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
|
tretinoin
Sensitive: D – Preclinical
|
